GRNA Stock

Description:

GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. It provides cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company's plant and animal health pipeline includes Calantha for the Colorado potato beetle; Varroa mites, an RNA-based syrup that targets reproductive mites; Vegetable Caterpillar Complex, an dsRNA-based pesticide for the Diamond Back Moth; and Spider Mite Complex for the control of Tetranychus urticae. It also developing fungicides program for botrytis, fusarium, powdery mildew, downy mildew, Asian soybean rust, and rice blast; Gray Mold + for botrytis cinerea; Powdery mildew complex for the control of powdery mildew, caused by Erysiphe necator; and Mycotoxin control for Fusarium Head Blight, a cereal crop based diseases. In addition, the company also developing human health program comprising a phase I/II preclinical stage vaccine for COVID-19; and candidate selection vaccines for Shingles, and oncology. GreenLight Biosciences Holdings was formerly known as Environmental Impact Acquisition Corp. The company was founded in 2008 and is headquartered in Medford, Massachusetts.